Hypertensive heart disease: Bone marrow as a significant player in pathologic remodelling?

Journal of Hypertension

Volumn 30, Issue 9, 2012, Pages 1702-1705

  Simko, Fedor ^a,b,c   Paulis, Ludovit ^a,c  

^a Physics and Informatics   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD34 ANTIGEN; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; ELASTIN; FIBRONECTIN; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; LAMININ; MICROSOMAL AMINOPEPTIDASE; TRANSFORMING GROWTH FACTOR BETA1;

BONE MARROW; CELL PROLIFERATION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROSIS; GENOTYPE; HEART DISEASE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPERTENSIVE HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION;

EID: 84865509662     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328357ad9c     Document Type: Review

References (30)

1. Díez J. Towards a new paradigm about hypertensive heart disease. Med Clin North Am 2009; 93:637-645.
2. Simko F, Pechanova O. Remodelling of the heart and vessels in experimental hypertension: advances in protection. J Hypertens 2010; 28 (Suppl 1):S1-S6.
3. Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006; 21:20-23. (Pubitemid 43057102)
4. Ciulla MM, Paliotti R, Esposito A, Cuspidi C, Muiesan ML, Rosei EA, et al. Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalapril. J Hypertens 2009; 27:626-632.
5. Kahan T. The importance of myocardial fibrosis in hypertensive heart disease. J Hypertens 2012; 30:685-687.
6. Pelouch V, Jirmar R. Biochemical characteristics of cardiac collagen and its role in ventricular remodelling following infarction. Physiol Res 1993; 42:283-292.
7. Shirwany A, Weber KT. Extracellular matrix remodeling in hypertensive heart disease. J Am Coll Cardiol 2006; 48:97-98.
8. Weber KT, Sun Y, Díez J. Fibrosis: a living tissue and the infarcted heart. J Am Coll Cardiol 2008; 52:2029-2031.
9. Diamond JA, Phillips RA. Hypertensive heart disease. Hypertens Res 2005; 28:191-202. (Pubitemid 40812602)
10. Díez J. Diagnosis and treatment of myocardial fibrosis in hypertensive heart disease. Circ J 2008; 72 (Suppl A):A8-A12.
11. Drazner MH. The progression of hypertensive heart disease. Circulation 2011; 123:327-334.
12. Simko F. Statins: a perspective for left ventricular hypertrophy treatment. Eur J Clin Invest 2007; 37:681-691. (Pubitemid 47256168)
13. Paulis L. Unger T Novel therapeutic targets for hypertension. Nat Rev Cardiol 2010; 7:431-441.
14. Weber KT. From inflammation to fibrosis: a stiff stretch of highway. Hypertension 2004; 43:716-719. (Pubitemid 38405574)
15. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117:568-575. (Pubitemid 46348511)
16. Bucala R, Spiegel LA, Chesney J, Hogan M, Cerami A. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994; 1:71-81.
17. Gomperts BN, Strieter RM. Fibrocytes in lung disease. J Leukoc Biol 2007; 82:449-456. (Pubitemid 47367134)
18. Metz CN. Fibrocytes: a unique cell population implicated in wound healing. Cell Mol Life Sci 2003; 60:1342-1350. (Pubitemid 36900518)
19. Keeley EC, Mehrad B, Janardhanan R, Salerno M, Hunter JR, Burdick MM, et al. Elevated circulating fibrocyte levels in patients with hypertensive heart disease. J Hypertens 2012; 30:1856-1861.
20. Zannad F, Dousset B, Alla F. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001; 38:1227-1232. (Pubitemid 34252836)
21. Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179:588-594.
22. Xu J, Lin SC, Chen J, Miao Y, Taffet GE, Entman ML, Wang Y. CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis. Am J Physiol Heart Circ Physiol 2011; 301:H538-H547.
23. Haudek SB, Cheng J, Du J, Wang Y, Hermosillo-Rodriguez J, Trial J, et al. Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy. J Mol Cell Cardiol 2010; 49:499-507.
24. Sopel M, Falkenham A, Oxner A, Ma I, Lee TD, Légaré JF. Fibroblast progenitor cells are recruited into the myocardium prior to the development of myocardial fibrosis. Int J Exp Pathol 2012; 93:115-121.
25. Keeley EC, Mehrad B, Strieter RM. The role of fibrocytes in fibrotic diseases of the lungs and heart. Fibrogenesis Tissue Repair 2011; 4:2.
26. Bernatova I, Pechanova O, Simko F. Effect of captopril in L-NAMEinduced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol 1999; 84:1095-1105.
27. Zanchetti A. A welcome debate on how to measure the left ventricular mass. J Hypertens 1997; 15:799.
28. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, et al. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004; 114:438-446. (Pubitemid 39071616)
29. Haudek SB, Xia Y, Huebener P, Lee JM, Carlson S, Crawford JR, et al. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci USA 2006; 103:18284-18289. (Pubitemid 44871650)
30. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004; 36:598-606. (Pubitemid 38316817)